相关实验视频
Updated: Jul 12, 2025
07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
17.9K
早期的慢性压力在散发性阿尔茨海默氏症中诱导了心脏部位内的变化
Donné Minné1,2, Jeanine L Marnewick1, Penelope Engel-Hills2
1Applied Microbial & Health Biotechnology Institute, Cape Peninsula University of Technology, Cape Town, 7535, South Africa.
Current Alzheimer research
|October 24, 2023
概括
慢性压力可能会引发阿尔茨海默病 (AD),因为它会导致大脑中异常的蛋白积聚,在症状出现几十年之前. 管理压力可以为早期AD预防提供治疗窗口.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 压力研究 压力研究
背景情况:
- 慢性压力与阿尔茨海默病 (AD) 病理生理学共享生物机制.
- 早期的AD异常涉及压力敏感的局部神经元中的酸化.
研究的目的:
- 介绍全静电负荷作为理解AD神经病理学的框架.
- 探索早期陶积累在AD级联中的作用.
主要方法:
- 使用全静电负荷的概念框架.
- 对与慢性压力和AD相关的神经病理变化的审查.
主要成果:
- 异常的 tau 在 locus coeruleus 在阿尔茨海默病的症状之前几十年.
- 慢性压力诱导的会引发刺激毒性,炎症,氧化应激和粉样蛋白恶化.
- 静态负荷整合了这些相互作用的病理变化.
结论:
- 早期tau积累在位点coeruleus-norepinephrine通路中是AD的一个潜在的初级事件.
- 管理压力和平衡HPA轴可能为AD预防提供治疗窗口.
关键词:
LC LC LC LC LC LC LC LC LC塔乌·塔乌 (Tau Tau) 是一个静态负荷的全静态负荷.慢性压力是一种慢性压力.痴呆症 痴呆症是一种痴呆症.神经退行症的神经退行症神经主义神经主义.北上腺氨酸 (norepinephrine) 是一种更多相关视频
07:26Assessing Pupil-linked Changes in Locus Coeruleus-mediated Arousal Elicited by Trigeminal Stimulation
Published on: November 26, 2019
8.1K
14:57Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
94.2K
相关概念视频
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200